Expression and bioactivity of recombinant canine erythropoietin

James N. MacLeod From the Department of Biomedical Sciences, James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853. Mr. Tetreault's present address is SUNY Health Sciences Center, College of Medicine, Syracuse, NY 13210.

Search for other papers by James N. MacLeod in
Current site
Google Scholar
PubMed
Close
 VMD, PhD
,
Jonathan W. Tetreault From the Department of Biomedical Sciences, James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853. Mr. Tetreault's present address is SUNY Health Sciences Center, College of Medicine, Syracuse, NY 13210.

Search for other papers by Jonathan W. Tetreault in
Current site
Google Scholar
PubMed
Close
 BS
,
Kellie A. S. Lorschy From the Department of Biomedical Sciences, James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853. Mr. Tetreault's present address is SUNY Health Sciences Center, College of Medicine, Syracuse, NY 13210.

Search for other papers by Kellie A. S. Lorschy in
Current site
Google Scholar
PubMed
Close
 BVSc
, and
Da Nian Gu From the Department of Biomedical Sciences, James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853. Mr. Tetreault's present address is SUNY Health Sciences Center, College of Medicine, Syracuse, NY 13210.

Search for other papers by Da Nian Gu in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

Objective

To produce recombinant canine erythropoietin (rcEPO) and compare its biological activity with that of recombinant human EPO (rhEPO).

Animals

C57BL/6J mice.

Procedure

The gene encoding cEPO was isolated from a genomic library and subcloned into an eucaryotic expression vector. Production of rcEPO was achieved by stable transfection of the expression construct into Chinese hamster ovary cells. Biological activity was evaluated in vitro by analyzing the mitogenic activity of rcEPO on murine erythroid progenitor cells. In vivo bioactivity was assessed in mice by measuring the ability of rcEPO to increase blood reticulocyte counts.

Results

Size and glycosylation of rcEPO expressed in Chinese hamster ovary cells were similar to values for commercial rhEPO. Canine and human EPO stimulated proliferation of murine erythroid progenitor cells in vitro and murine reticulocytosis in vivo in a dosedependent manner.

Conclusions

Comparable biological activity was observed for rcEPO and rhEPO in the 2 murine-based assay systems studied. By avoiding interspecies variation in protein structure and the resulting potential for immunogenicity, rcEPO should represent a better option than rhEPO for treatment of dogs with erythropoietin-dependent anemia.

Clinical Relevance

Therapeutic use of rhEPO in companion animals is limited by its immunogenicity and the resulting potential to induce pure red cell aplasia. Development and availability of species-specific EPO preparations should avoid this problem. (Am J Vet Res 1998;59:1144-1148)

Abstract

Objective

To produce recombinant canine erythropoietin (rcEPO) and compare its biological activity with that of recombinant human EPO (rhEPO).

Animals

C57BL/6J mice.

Procedure

The gene encoding cEPO was isolated from a genomic library and subcloned into an eucaryotic expression vector. Production of rcEPO was achieved by stable transfection of the expression construct into Chinese hamster ovary cells. Biological activity was evaluated in vitro by analyzing the mitogenic activity of rcEPO on murine erythroid progenitor cells. In vivo bioactivity was assessed in mice by measuring the ability of rcEPO to increase blood reticulocyte counts.

Results

Size and glycosylation of rcEPO expressed in Chinese hamster ovary cells were similar to values for commercial rhEPO. Canine and human EPO stimulated proliferation of murine erythroid progenitor cells in vitro and murine reticulocytosis in vivo in a dosedependent manner.

Conclusions

Comparable biological activity was observed for rcEPO and rhEPO in the 2 murine-based assay systems studied. By avoiding interspecies variation in protein structure and the resulting potential for immunogenicity, rcEPO should represent a better option than rhEPO for treatment of dogs with erythropoietin-dependent anemia.

Clinical Relevance

Therapeutic use of rhEPO in companion animals is limited by its immunogenicity and the resulting potential to induce pure red cell aplasia. Development and availability of species-specific EPO preparations should avoid this problem. (Am J Vet Res 1998;59:1144-1148)

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 5912 5898 72
PDF Downloads 57 41 0
Advertisement